US2014056925A1PendingUtilityA1

Methods of Reducing Myocardial Injury Following Myocardial Infarction

53
Assignee: UNIV EAST CAROLINAPriority: Nov 17, 2010Filed: Nov 6, 2013Published: Feb 27, 2014
Est. expiryNov 17, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Jitka ViragJessica L. Dries
A61K 38/177A61K 9/0019C07K 2319/30A61K 38/19C07K 14/705A61K 38/17A61P 9/00A61P 9/10A61K 45/06
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising:
 an ephrin; and   a pharmaceutically acceptable carrier.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is a parenteral composition. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the parenteral composition is selected from the group consisting of a subcutaneous, intramuscular, intradermal, intraarticular, intrapleural, intraperitoneal, intrathecal, intracerebral, intracranially, intramyocardial, intraarterial and intravenous composition. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the parenteral composition is an intravenous composition. 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein the parenteral composition is an intramyocardial composition. 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the parenteral composition is a subcutaneous composition. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is a controlled or delayed release composition. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the controlled or delayed release composition is an implantable composition. 
     
     
         9 . The pharmaceutical composition of  claim 7 , wherein the controlled or delayed release composition is a nanoparticle composition. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the ephrin is an ephrin-A class ephrin. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the ephrin is ephrin A1, ephrin A2, ephrin A3, ephrin A4, ephrin A5, or a combination thereof. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein the ephrin is ephrin A1. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the ephrin comprises ephrinA1-Fc. 
     
     
         14 . The pharmaceutical composition of  claim 1  further comprising an agent useful for treating myocardial infarction. 
     
     
         15 . A kit comprising a composition comprising an ephrin in a pharmaceutically acceptable carrier and a container suitable for delivery of the composition into a parenteral administration device optionally comprising instructions for use of the components of the kit. 
     
     
         16 . The kit of  claim 15 , wherein the parenteral administration device is an intramyocardial administration device. 
     
     
         17 . The kit of  claim 15 , wherein the ephrin is an ephrin-A class ephrin. 
     
     
         18 . The kit of  claim 15 , wherein the ephrin is ephrin A1, ephrin A2, ephrin A3, ephrin A4, ephrin A5, or a combination thereof. 
     
     
         19 . The kit of  claim 15 , wherein the ephrin is ephrin A1. 
     
     
         20 . The kit of  claim 15 , wherein the ephrin comprises ephrinA1-Fc.

Join the waitlist — get patent alerts

Track US2014056925A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.